The startup is developing a portfolio of dry powder nasal medications specifically designed for the rapid treatment of anaphylaxis. This approach provides patients with a convenient and effective method to receive emergency care, ensuring timely intervention during critical allergic reactions.
Funding
$18.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current epinephrine auto-injectors for anaphylaxis treatment have limitations, including needle phobia, potential for user error, and instability in extreme temperatures, hindering accessibility and ease of use, particularly in underserved regions. Many individuals at risk do not carry or use epinephrine due to these factors, leading to potentially life-threatening delays in treatment.
Solution
Belhaven Biopharma is developing Nasdepi, a dry powder nasal epinephrine product designed for rapid treatment of severe allergic reactions. This needle-free alternative aims to overcome the limitations of traditional auto-injectors by offering a more convenient, pain-free, and user-friendly delivery method. The dry powder formulation enhances stability in diverse climates and extends shelf life, improving accessibility in areas where conventional epinephrine products are unavailable or impractical. Nasdepi is engineered for rapid absorption and ease of use, empowering patients to administer life-saving medication quickly and confidently during anaphylactic emergencies.
Target Audience
The primary target audience includes individuals with severe allergies, their caregivers, outdoor workers, travelers, and underserved populations in regions with limited access to traditional epinephrine auto-injectors.
Features
- Needle-free nasal delivery eliminates injection-related anxiety and risk of injury.
- Dry powder formulation enhances temperature stability and extends shelf life compared to liquid epinephrine products.
- Compact and intuitive device design ensures ease of use, even for untrained individuals or when the recipient is unconscious.
- Rapid absorption technology facilitates quick delivery of epinephrine into the bloodstream.
- Lightweight and resilient construction suitable for diverse environments and travel.
- Designed for ease of disposal and reduced waste.